Meeting
2016 Genitourinary Cancers Symposium
Serum parathyroid hormone and calcium changes in metastatic castration resistant prostate cancer patients receiving enzalutamide in post-docetaxel setting.
Authors
Angela Gernone
Medical Oncology Unit, Piazzale Giulio Cesare, 11 Policlinico Hospital, Bari, Italy
Angela Gernone , Maria Nicla Pappagallo , Francesco Silvestris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 349)
DOI
10.1200/jco.2016.34.2_suppl.349
Abstract #
349
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco
Poster
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
First Author: Jordan Bauman
Poster
2019 Genitourinary Cancers Symposium
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia S. Higano
Poster
2017 Genitourinary Cancers Symposium
Evaluation of treatment patterns and costs for patients with prostate cancer and bone metastases.
First Author: Adriana Valdarrama